On December 21, Lizhu Pharmaceutical issued an announcement stating that the wholly-owned subsidiary has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration regarding the addition of NS-041 tablets for treatment of depression, and agreed to carry out clinical trials with additional indications for NS-041 tablets. According to data, this pharmaceutical line is currently the only KCNQ2/3 agonist approved in China to simultaneously conduct clinical studies on epilepsy and depression.

On December 21, Lizhu Pharmaceutical issued an announcement stating that the wholly-owned subsidiary has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration regarding the addition of NS-041 tablets for treatment of depression, and agreed to carry out clinical trials with additional indications for NS-041 tablets. According to data, this pharmaceutical line is currently the only KCNQ2/3 agonist approved in China to simultaneously conduct clinical studies on epilepsy and depression.